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Abstract
The diagnosis and treatment of synucleinopathies such as Parkinson disease and dementia with Lewy bodies would be
aided by the availability of assays for the pathogenic disease-associated forms of α-synuclein (αSynD) that are sufficiently
sensitive, specific, and practical for analysis of accessible diagnostic specimens. Two recent αSynD seed amplification tests
have provided the first prototypes for ultrasensitive and specific detection of αSynD in patients’ cerebrospinal fluid. These
prototypic assays require 5–13 days to perform. Here, we describe an improved α-synuclein real time quaking-induced
conversion (αSyn RT-QuIC) assay that has similar sensitivity and specificity to the prior assays, but can be performed in
1–2 days with quantitation. Blinded analysis of cerebrospinal fluid from 29 synucleinopathy cases [12 Parkinson’s and 17
dementia with Lewy bodies] and 31 non-synucleinopathy controls, including 16 Alzheimer’s cases, yielded 93% diagnostic
sensitivity and 100% specificity for this test so far. End-point dilution analyses allowed quantitation of relative amounts of
αSynD seeding activity in cerebrospinal fluid samples, and detection in as little as 0.2 μL. These results confirm that αSynD
seeding activity is present in cerebrospinal fluid. We also demonstrate that it can be rapidly detected, and quantitated,
even in early symptomatic stages of synucleinopathy.
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Introduction
Many neurodegenerative diseases are related to the accu-
mulation of specific misfolded proteins. These deposits are
identified upon post-mortem analysis of brain tissue, allow-
ing definite diagnoses to be made based on specific neuro-
pathological and molecular findings. Less definitive intra
vitam diagnoses can be proffered based on specific clinical
signs, tissue imaging data, pathological examination of per-
ipheral biopsies, and less-than-specific biomarker levels in
the CSF. In particular, early diagnosis can be difficult and
discrimination between diseases can be complicated by
clinical variability and overlaps in clinical features.
Parkinson’s disease (PD), multiple system atrophy (MSA),
dementia with Lewy bodies (DLB) [or Lewy body dementia]
are called α-synucleinopathies due to the abnormal accu-
mulation of aggregates of a protein called α-synuclein
(αSyn) in the brain. Although the clinical diagnosis of par-
kinsonism can be relatively simple, the specific diagnosis of
PD, especially at early stages, can be difficult. Adler et al.
noted that in patients with possible PD (never treated or
not clearly responsive to L-dopa) only 26% had autopsy
confirmation as PD, while in probable PD (responsive to
medications) the diagnostic accuracy was 82% [1]. In DLB,
clinical diagnostic criteria for probable DLB predict αSyn
pathology with sensitivity of about 80% [18] but early diag-
nosis of DLB is less accurate due to the overlapping symp-
toms with other types of dementia. In addition, in 15–20%
of patients with Alzheimer disease (AD) at autopsy,
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concomitant DLB pathology can be found, with only a mi-
nority of patients having exhibited clear diagnostic fea-
tures of DLB [20, 34]. However, in patients with AD and
diffuse Lewy body pathology, disease duration was short-
ened [11], indicating that DLB pathology contributes to
dementia progression.
Some pertinent tests indirectly measure the effect of
α-Syn pathology (e.g., dopamine receptor SPECT or PET
scans, and MIBG cardiac scintigraphy), while the sensi-
tivity and specificity of skin, salivary gland and colonic
biopsy for PD or DLB has not been established in large
scale studies. In these clinical settings of PD and DLB,
the presence of a biomarker that indicates that abnormal
pathological forms of a αSyn are present would improve
diagnostic accuracy not only for prognostic purposes but
also for cohort selection in disease-modifying clinical tri-
als for PD. Attempts to determine if cerebrospinal fluid
(CSF) levels of total, phosphorylated or oligomeric a-syn
are diagnostically useful have been variable and contro-
versial between studies [reviewed in [27]], and the diag-
nostic utility of immunoassays for these forms of αSyn
in CSF remains unclear [21, 31].
However, two recent studies have provided evidence
that analysis of a distinct feature of disease-associated
forms of αSyn (hereafter abbreviated αSynD), namely
their amyloid seeding activity, may have substantial diag-
nostic utility for PD and DLB [7, 35]. The rationale for
the seeding activity assays is that the αSynD deposits
contain fibrils, or subfibrillar oligomers, that propagate
by a seeded polymerization mechanism in which αSynD
templates, or seeds, conversion of non-fibrillar αSyn into
larger oligomeric or aggregate, fibrillar forms. Mechanis-
tically similar assays called Real-Time Quaking-Induced
Conversion (RT-QuIC) have provided ultrasensitive, spe-
cific and quantitative diagnostic tests for prion diseases
[2, 39]. RT-QuIC assays are multi-well plate-based reac-
tions that can rapidly amplify oligomeric/multimeric
prion seeds by as much as a trillion-fold [8, 24, 26, 39].
Prion RT-QuIC assays have been applied successfully to
a variety of biological samples including brain [29, 39,
41], cerebrospinal fluid (CSF) [2, 5, 17, 24, 33], whole
blood, plasma [26, 38], urine [14], and nasal brushings
[23, 40]. They are being widely implemented for the
diagnosis of prion diseases in humans and animals. Not-
ably, our recent studies demonstrated provisional 100%
diagnostic sensitivity and specificity in diagnosing hu-
man sporadic Creutzfeldt-Jakob disease using CSF and/
or nasal swabs [4].
Green and colleagues adapted the RT-QuIC approach to
synucleinopathies and applied it to a total of 137 PD and
DLB cases and controls [7]. Their assay (αSyn RT-QuIC)
has given 95 and 92% sensitivity for PD and DLB patients,
respectively, with 100% specificity. Soto and colleagues de-
veloped a similar assay called αSyn protein misfolding
cyclic amplification (αSyn-PMCA) which gave 89% sensi-
tivity for PD and 97% specificity in analyses of 173 total
cases and controls [35]. In these assays, 5–40 μl aliquots
of CSF are added to reactions containing recombinant
αSyn (rαSyn). Any αSynD seeds in the sample initiate
amyloid fibril formation by the recombinant αSyn which,
in turn, enhances the fluorescence of thioflavin T (ThT).
The reactions are performed over ~ 5 [7] to 13 days [35].
Sano and colleagues have described an αSyn RT-QuIC
assay that detects DLB αSynD seeding activity in brain tis-
sue at extreme dilutions in < 4 days [32]. Bernis and col-
leagues showed that 10% brain homogenate samples from
mice inoculated with human MSA or incidental Lewy
body disease brain tissue could seed fibrillization of rαSyn
in 1–2 days [3]. Here we report that by using a mutant
rαSyn substrate and optimized reaction conditions, αSyn
RT-QuIC assays on CSF specimens can be completed
within 1–2 days with high diagnostic sensitivity and
specificity.
Materials and methods
Clinical assessment
All subjects provided consent to clinical assessment, in-
cluding longitudinal follow-up, and to lumbar puncture to
obtain CSF, under UCSD IRB-approved protocol #080012.
All procedures performed in this study were in accordance
with the 1964 Helsinki declaration and its later amend-
ments or comparable ethical standards. Some subjects
died during the follow-up period, and had consented to
their brains being obtained at autopsy.
All subjects underwent a detailed clinical research assess-
ment, including review of outside medical records, history
of cognitive and motor symptoms, mental state examin-
ation with the Mini-Mental State Exam or Montreal
Cognitive Assessment, and detailed neuropsychological
testing, structured physical neurological examination, in-
cluding the Unified Parkinson’s Disease Rating Scale
(UPDRS) Part III motor examination. All subjects were en-
rolled in a research protocol that allowed annual follow-up
reassessment and received at least one follow-up assess-
ment after their baseline visit. Neuroimaging (MRI and in
some instances FDG PET scan or DaTscan) results were
reviewed when available. The research diagnoses were
made by consensus of two neurologists who reviewed all of
the available clinical information. Research diagnoses
followed published criteria: controls had no history of
major neurological or psychiatric illness and were normal
on cognition and neurological examination; patients with
AD met criteria for probable AD (NIA-AA 2011). For PD,
criteria proposed by the Movement Disorder Society were
used [30], and research guidelines were applied to diagnose
PD-MCI [16], PD-dementia and DLB (possible and prob-
able DLB were diagnosed according to McKeith [19]).
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Lumbar puncture and CSF handling
Lumbar punctures (LPs) were performed in the early
morning, after a fast of at least 8 h. Subjects were either
sitting or lying, and LPs were performed with sterile
technique using an atraumatic needle. CSF (15–20 mL)
was withdrawn into a polypropylene tube and a sample
was sent for analysis of cell count, total protein and glu-
cose to a local laboratory. The remaining CSF was gently
mixed, centrifuged at 1500 g for 10 min, then aliquotted
in 500 μL fractions into polypropylene cryotubes, flash
frozen and stored at − 80 °C.
Autopsy brain analysis
Procedures at autopsy at the UCSD Alzheimer’s Disease
Research Center are as follows: the brain is divided sagit-
tally and the left hemibrain is fixed in 10% buffered for-
malin while the right hemibrain is sectioned coronally
and then frozen at − 70 °C in sealed plastic bags.
Routinely, tissue blocks from the right hemibrain of the
midfrontal, inferior parietal, and superior temporal corti-
ces, primary visual cortex in the occipital cortex, hippo-
campus, basal ganglia, substantia nigra and cerebellum
are removed and placed in 2% paraformaldehyde for
subsequent thick sectioning by vibratome. Tissue blocks
adjacent to the ones described above are stored at − 70 °
C for subsequent immunoblot analysis for synaptic pro-
teins and Aβ species (soluble and oligomers). Vibratome
sections (40 μm thick) are stored in cryoprotective
medium at − 20 °C for subsequent immunochemical
studies. The formalin-fixed left hemibrain is serially sec-
tioned in 1 cm slices and tissue blocks from the regions
described above are processed for histopathological
examination by H&E, and Thioflavin-S (Thio-S) to de-
tect tau and β-amyloid deposits. Lewy body pathology is
evaluated using phosphorylated α-synuclein immunore-
activity with a mouse monoclonal antibody at 1:20,000
(BioLegend Cat# 825701 RRID:AB 2564891). Patho-
logical diagnoses of AD and DLB are made using
National Institute on Aging-Alzheimer’s Association
(NIA-AA) guidelines [22].
K23Q rαSyn expression vector preparation
DNA sequences coding for human α-synuclein se-
quence (Accession No. NM_000345.3) amino acid resi-
dues 1–140 (wildtype) were amplified and ligated into
the pET24 vector with an N-terminal His-tag (EMD
Biosciences) and sequences were confirmed. The α-
synuclein K23Q mutation [15] was engineered using
Q5 Site-Directed Mutagenesis (NEB) using the primers
CCACACCCTGTTGGGTTTTCTCAG and CAGAAG-
CAGCAGGAAAGAC. The plasmids were transformed
into BL21(DE3) Escherichia coli (EMD Biosciences).
rαSyn protein purification
Five ml of LB media containing 50 μg/mL kanamycin were
inoculated from a glycerol stock of E. coli bacteria contain-
ing vectors either for wildtype (WT) or K23Q rαSyn pro-
tein expression. Following 4–5-h incubation with
continuous 225 rpm agitation at 37 °C, 1 L of the auto-
induction media [9] also containing 50 μg/mL kanamycin
was prepared and the 5 mL starter culture was added. The
cells were grown in a shaking incubator at 37 °C, 225 rpm,
overnight. The next day cells were harvested by splitting
the 1 L culture into four 250 ml conical tubes and centrifu-
ging at 3273×g, 4 °C, 10 min.
Cells were lysed using an osmotic shock protocol modi-
fied from Paslawski et al. [28]. Using a 25 mL serological
pipette, the cell pellets were gently resuspended in 10% vol-
ume of room temperature osmotic shock buffer, (25 mL
per 250 mL of cell culture before centrifugation) and incu-
bated at room temperature for 10 min. The suspension was
centrifuged at 9000×g, 20 °C, 20 min. The supernatant was
discarded and the pellet was gently resuspended in 10 mL
of ice-cold water per pellet, using a 25 mL serological pip-
ette. The cell suspensions were pooled into two 50 mL
tubes to 20 ml each. 20 μL of saturated MgCl2 was added
to each 20 mL suspension. The suspension was then mixed
and incubated on ice with mild rocking for 3 min. Next,
the suspension was centrifuged at 9000×g, 4 °C, 30 min.
The supernatant was collected in a 100 ml glass beaker that
contained a stir bar for rapid continuous mixing while be-
ing careful not to incorporate air bubbles. The pH was re-
duced to pH 3.5 by adding a bolus of ~ 800 μl 1 M HCl
followed by additional 25 μl increments as necessary while
continuously monitoring the pH. A large amount of white
precipitate was generated. The suspension was then incu-
bated with gentle stirring at room temperature for 10 min,
avoiding the formation of air bubbles. The tubes were cen-
trifuged at 9000×g, 4 °C, 30 min, and the supernatant was
collected in a fresh 100 ml beaker using continuous agita-
tion with a stir bar. The pH was adjusted to 7.5 with an ~
800 μl bolus of 1 M NaOH followed by 25 μl increments as
necessary. The protein extract was then filtered through a
0.45 μm filter. Next, the extract was loaded onto a 5 ml Ni-
NTA column (Qiagen) on an Äkta Pure chromatography
system (GE) and washed with 20 mM Tris, pH 7.5 at room
temperature. The column was further washed with 50 mM
imidazole, 20 mM Tris, pH 7.5 which generated a peak that
was not collected. A linear gradient up to 500 mM imid-
azole in 20 mM Tris, pH 7.5, was performed and a peak
was collected between 150 and 375 mM imidazole
(Additional file 1). This peak was then loaded onto a Q-HP
column (GE) and washed with 20 mM Tris, pH 7.5. The
column was further washed with 100 mM NaCl, 20 mM
Tris, pH 7.5. A linear gradient up to 500 mM NaCl in
20 mM Tris pH 7.5 was performed and a peak was recov-
ered between 300 and 350 mM NaCl. The protein was
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filtered through a 0.22 μm filter and dialyzed against water
overnight at 4 °C using a 3 kDa MWCO dialysis membrane.
The next day, the protein was moved into fresh water for
another 4 h dialysis. The protein concentration was deter-
mined with a UV–VIS spectrophotometer using a theoret-
ical extinction coefficient at 280 nm of 0.36 (mg/mL)− 1 cm
− 1. The protein was lyophilized in aliquots and stored for a
final concentration of ~ 1.0 mg/ml once resuspended in
500 μL of 40 mM phosphate buffer (pH 8.0). These aliquots
were stored at − 80 °C until further use.
For comparative studies, human recombinant full-length
(1–140 aa) WT αSyn was also purchased from Stratech,
(Cambridge, UK).
Endotoxin concentration levels for rαSyn protein purifica-
tions was determined using a ToxinSensor Endotoxin Detec-
tion kit (GenScript) according to manufacturer’s protocol.
SDS-PAGE analysis
Samples were prepared in 2× sample loading buffer (final
concentration: 62.5 mM Tris–HCl, pH 6.8, 5% glycerol,
3 mM EDTA, 5% SDS, 0.02% bromophenol blue, 4 M urea,
4% β-mercaptoethanol) and boiled for 5 min. Proteins were
separated by gel electrophoresis using 10% Bis-TrisNuPAGE
gels (Invitrogen). For total protein analysis, gels were stained
with GelCode Blue Safe Protein Stain (Thermo Scientific,
24,594) according to the manufacture’s protocol.
Preparation of synthetic wildtype rαSyn fibrils
A 100 μL solution of 1 mg/ml WT rαSyn in PBS was sub-
jected to continuous 1000 rpm shaking at 37 °C for 3 days
in a 1.5 mL tube. The products were ThT-positive, indicat-
ing the presence of amyloid, and the OD280 and Western
blot comparisons of supernatants before and after centri-
fugation indicated that > 30% of the total rαSyn was insol-
uble and therefore aggregated.
Brain homogenate preparations
Brain homogenates (BH; 10% w/v) were prepared by hom-
ogenizing the tissue in PBS using a Bead Beater (Biospec
Products; 11079110z) for 1 min at maximum speed. The
homogenate was then spun at 2000 xg for 2 min at room
temperature and the supernatant was transferred to a new
tube and stored at − 80 °C for αSyn RT-QuIC analysis. For
αSyn RT-QuIC testing, BHs were serially diluted in PBS.
αSyn RT-QuIC protocol
RT-QuIC reactions were performed in black 96-well plates
with a clear bottom (Nalgene Nunc International). We
preloaded plates with 6 glass or silica beads (1 mm in
diameter, BioSpec Products or 0.8 mm, OPS Diagnostics,
respectively) per well. Silica beads were ultimately chosen
over the glass beads because of some occasional batch to
batch variability that was observed with the glass beads.
For brain homogenate seeded reactions, 2 μL of indicated
BH dilutions were added to wells containing 98 μL of the
reaction mix to give final concentrations of 40 mM phos-
phate buffer (pH 8.0), 170 mM NaCl, 0.1 mg/ml of the
designated rαSyn (filtered through a 100 kD MWCO filter
immediately prior to use), and 10 μM ThT. The plate was
then sealed with a plate sealer film (Nalgene Nunc Inter-
national) and incubated at 42 °C in a BMG FLUOstar
Omega plate reader with cycles of 1 min shaking
(400 rpm double orbital) and 1 min rest throughout the
indicated incubation time. ThT fluorescence measure-
ments (450 +/− 10 nm excitation and 480 +/− 10 nm
emission; bottom read) were taken every 45 min. After the
initial testing (data in Fig. 1) the fluorimeter gain settings
were adjusted to maintain the fluorescence response
within the readable range.
In the case of CSF seeded reactions, wells pre-loaded with
6 glass or silica beads were given 85 μL of a reaction mix
adjusted to give final reaction concentrations of 40 mM
phosphate buffer (pH 8.0), 170 mM NaCl, 0.1 mg/ml
rαSyn, 10 μM thioflavin T (ThT) and 0.0015% sodium do-
decyl sulfate (SDS) and then 15 μL CSF, or dilutions thereof
Fig. 1 Detection of αSyn seeding activity in BH and CSF using K23Q
(blue), WT (red) and WT* (green; commercial wild-type rαSyn lacking a
6× histidine tag [7]) substrates. Reactions were seeded in quadruplicate
with brain homogenate (BH) (top panel) or CSF (bottom panel) from
Parkinson’s disease (PD) or non-synucleinopathy (NS) including
corticobasal degeneration cases (CBD BH) and healthy donors
(NS CSF). For the BH assays, 10− 3 (closed symbols) or 10− 4 (open
symbols) brain tissue dilutions from a single PD or NS case were
used. For the CSF assays, 15 μl (undiluted) from two PD cases
and one NS case was used. Each sample trace represents the
average ThT signal of quadruplicate wells. For clarity only every
other data point is plotted. The vertical dashed line designates
the assay cutoff time used in subsequent analyses
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in normal pooled CSF. The reaction plates were subjected
to shake-rest cycles as for BH samples above and the reac-
tions classified as RT-QuIC-positive or -negative based on
criteria similar to those previously described for RT-QuIC
analyses of brain specimens [23, 39]. Briefly, a ThT fluores-
cence threshold was calculated as the average fluorescence
for all samples within the first 10 h of incubation, plus three
Standard Deviations (SD). A sample was considered
positive overall when at least two of four replicate wells
crossed this calculated threshold. When only one of the
quadruplicates crossed the threshold, the analysis was
repeated.
Results
Rapid detection of αSynD by αSyn RT-QuIC
In developing our αSyn RT-QuIC, we focused primarily on
a recombinant 6× histidine-tagged K23Q mutant of αSyn as
a soluble rαSyn substrate for αSynD-induced fibrillization.
Recombinant K23Q αSyn was reported to fibrillize with kin-
etics similar to wild-type (WT) αSyn when seeded with pre-
formed synthetic WT αSyn fibrils, but was slower to
spontaneously fibrillize in the absence of preformed seeds
[15]. This latter characteristic, we hypothesized, might im-
prove the sensitivity of an αSyn RT-QuIC assay by enhan-
cing the kinetic distinction between reactions seeded with
samples from synucleinopathy cases versus controls. We it-
eratively optimized the K23Q purification protocol and αSyn
RT-QuIC reaction conditions. The best purification protocol
to date involves lysis by osmotic shock followed by acid pre-
cipitation and sequential metal-ion affinity and ion exchange
chromatography steps [28]. No protein impurities were ob-
served by SDS-PAGE analyses of our K23Q mutant rαSyn,
our similar preparation of a histidine-tagged WT αSyn, or a
commercial wild-type αSyn preparation (without a 6× histi-
dine tag) (WT*) that was used for the previously described
αSyn RT-QuIC assay [7] (Additional file 1). However, be-
cause lipopolysaccharide (LPS) can contaminate bacterially
derived protein preparations and might influence fibrilliza-
tion, we assayed the three rαSyn preparations and found
that whereas our WT and K23Q rαSyn preparations were
negative for LPS in this assay (< 0.25 EU/ml), the WT* prep-
aration had ≥ 0.25 EU/ml LPS.
In the αSyn RT-QuIC assay itself, the sample volume,
SDS concentration, temperature, bead size and number
were particularly influential in improving the speed,
sensitivity and specificity of the αSyn RT-QuIC assay for
clinical samples (data not shown). Analyses of brain
homogenates (BH) and CSF samples from a small initial
set of synucleinopathy (PD and DLB) cases and non-
synucleinopathy (NS) cases indicated that, whereas the NS
brain and CSF specimens gave no positive RT-QuIC
reactions above a threshold fluorescence (see Materials
and Methods) over the 48-h reaction period, the PD and
DLB samples gave positive responses within ~ 18–35 h for
BH and ~ 15–24 h for CSF (Figs. 1 and 2; Additional
file 2). When prepared in this way, K23Q (Fig. 1, blue
traces) and WT rαSyn (red traces) gave similar responses
to seeding with PD brain tissue (10− 3–10− 4 dilutions;
Fig. 1A; Additional file 2) or CSF (15 μl; Fig. 1B; Additional
file 2) but the WT rαSyn was more prone to give modest
increases in ThT fluorescence in negative control reac-
tions. The WT* rαSyn (green traces), had slower re-
sponses and lower maximum ThT fluorescence readings
when seeded with PD samples than our WT and K23Q
rαSyn substrate preparations. We do not know how the
WT* rαSyn was prepared, so either its preparation, its lack
of 6× histidine tag, or LPS contamination might be re-
sponsible for its weaker responses to seeding compared to
our preparations of WT and K23Q rαSyn. With the more
rapid PD-seeded reactions with our K23Q or WT rαSyn
substrates, we observed decreases in average ThT fluores-
cence after maximum fluorescence had been achieved.
We have observed similar decreases in prion RT-QuIC
reactions (e.g. [24]), but their cause has not been deter-
mined. Based on these data and the previously published
work [15] we have used our K23Q mutant rαSyn prepara-
tions in subsequent experiments.
Blinded analysis of CSF from synucleinopathy cases and
controls
We performed blinded analyses of a larger set of CSF speci-
mens obtained antemortem from synucleinopathy cases and
Fig. 2 Detection of αSyn seeding activity in BH (a) and CSF (b)
from cases with DLB but not non-synucleinopathy cases using
K23Q rαSyn. Two μl of 10−3 dilutions of DLB (red; n = 3) or CBD
(gray; n = 3) BH, or 15 μl (undiluted) CSF from DLB (red; n = 3) or
healthy donors (NS CSF, gray; n = 3) were used per reaction. Each
trace represents the average ThT signal of the four replicate wells
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controls described in Table 1 and Additional file 3. AD cases
(n= 16) were included as examples of a neurodegenerative
protein misfolding disease that usually, but not always [10],
lacks synucleinopathy. As such AD cases were analyzed as a
separate category from NS samples. Other types of NS sam-
ples, including two progressive supranuclear palsy cases and
one corticobasal degeneration case, were also included as
controls. For many of the synucleinopathy (PD and DLB)
cases, the CSF specimens were collected early in the overall
clinical course of disease (Additional file 3). For 8 subjects
with PD, the CSF was obtained while motor symptoms
and signs were still too mild to warrant treatment with L-
dopa or another drug with dopaminergic actions (de novo
PD). The consensus diagnosis at follow-up or, if available,
the autopsy diagnosis was used as the gold standard diag-
nosis. Final diagnoses of cases and controls based on 1 year
or longer of clinical follow up after the LP, and/or autopsy
examination of the brain, was thus used as the final diag-
nosis (Additional file 3). Two cases (13/020 and 14/045 in
Additional file 3) were initially diagnosed with AD but
with progression had recurring visual hallucinations that
are the most robust of the clinical features that predict
DLB. Thus, on follow-up, these cases were given diagno-
ses of possible DLB.
Almost all of the PD (11/12) and DLB (16/17) CSF sam-
ples, including those obtained from the two possible DLB
cases, gave positive RT-QuIC responses within 15–35 h
(Fig. 3). The average reaction time required to exceed our
designated positivity threshold (see Materials and Methods)
was similar for the PD and DLB specimens (Fig. 3c). Not-
ably, most of the control cases without any clinical or
neuropathological (when available) indication of synuclei-
nopathy were negative in all 4 replicate αSyn RT-QuIC re-
actions. One case (15/044 in Additional file 3) with a
diagnosis of primary progressive aphasia and frontotem-
poral dementia was positive in 1 of 4 replicate reactions in
two independent assays (Fig. 3b; blue “x”). Although it did
not meet our criterium of having ≥2 of 4 positive replicate
reactions for an overall designation as a positive sample,
this case might represent an atypical case of DLB with a
clinical diagnosis of primary progressive aphasia [12] with
marginally detectable amounts of αSynD in the CSF. No
αSynD was detected by immunostaining in the midfrontal,
inferior parietal, and superior temporal cortices, primary
visual cortex in the occipital cortex, hippocampus, basal
ganglia, substantia nigra and cerebellum; however, this ana-
lysis did not include the amygdala, which can be an initial
site of αSynD accumulation. Thus, while not meeting cri-
teria to be considered positive for αSynD seed activity, we
cannot rule out the presence of some αSynD pathology in
this patient at this time.
Overall, the results from this blinded panel indi-
cated diagnostic sensitivities, i.e. the percentage of
cases giving positive RT-QuIC responses, of 93% for
both PD and DLB. None of the non-synucleinopathy
or AD controls met criteria to be considered positive
RT-QuIC responses resulting in an apparent specifi-
city of 100%.
Relative αSyn seeding activities in CSF and brain tissue
from PD and DLB cases
To quantify the αSyn RT-QuIC seeding activities in samples
from synucleinopathy cases, we performed end-point dilu-
tion analyses of frontal cortex brain tissue from representa-
tive PD (n = 1) and DLB (n = 3) cases and CSF samples
from 5 DLB cases. All 4 brain samples indicated that posi-
tive reactions were obtained out to 10− 5–10− 6 dilutions of
either the PD and DLB tissues (Fig. 4). Positive reactions
were obtained from as little as 0.2 μl CSF per reaction well
in DLB cases (Fig. 4). Spearman-Kärber analyses [6] pro-
vided estimates of the concentrations of seeding activity
units giving positive reactions in 50% of replicate reactions,
i.e., the 50% “seeding doses” or SD50s [39] (Fig. 4). The DLB
and PD brain samples contained ~ 105-106 SD50 per mg of
tissue while the CSF samples had 4–54 SD50s per 15 μl, i.e.,
our usual sample volume. The latter results indicated that
these synucleinopathy CSF specimens had seeding activities
that are substantially higher than the minimum detectable
level of 1 SD50. However, on a per weight basis, seeding
activity in brain tissue appeared to be 104–105-fold
higher than the seeding activities measured in PD and
DLB CSF specimens (Fig. 4). We note that slightly
different conditions were used for the brain homogen-
ate and CSF specimens because neither of the reac-
tion conditions alone was well suited for detecting
seeding activity in both types of samples. These
Table 1 Demographic data and cognitive impairment at the time of lumbar puncture (LP) in studied subjects
Final diagnosis n Age at onset (years) Age at LP (years) Mean interval between
onset and LP (years)
Sex (M:F) MMSEa
Dementia with Lewy Bodies 17 69.6 ± 7.8 73.8 ± 7.8 4.2 17:2 23.0 ± 4.6
Parkinson’s Disease 12 63.1 ± 12.0 66.0 ± 12.9 2.9 11:1 28.9 ± 1.1
Alzheimer’s Disease 16 69.9 ± 9.1 73.9 ± 9.1 4 12:4 22.9 ± 3.3
Controlb 12 n/a 71.3 ± 7.0 n/a 4:8 28.8 ± 1.2
Otherb 3 65.7 ± 11.4 67.7 ± 10.7 2 2:1 20.5 ± 8.1
aMMSE: Mini–Mental State Examination, b“controls” and “others” were grouped into “non-synucleinopathies” for analysis
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Fig. 4 End-point dilutions of synucleinopathy BH (a; sample # 081017) or CSF (b; sample # 10/005) samples by αSyn RT-QuIC. Each sample trace
represents the average ThT signal of quadruplicate wells. Tables to the right of each graph indicate the concentration of SD50 units calculated by
Spearman-Kärber analysis for these, and additional, cases. End-point dilution experiments used for the additional calculated values shown in the
upper and lower panels are provided in Additional files 4 and 5, respectively
Fig. 3 Blinded testing of CSF samples by α-synuclein RT-QuIC. Samples from non-synucleinopathy (NS), Alzheimer’s disease (AD), dementia with Lewy
bodies (DLB) or Parkinson’s disease (PD) patients, were tested blinded using the K23Q substrate. Quadruplicate reactions were seeded with 15 μL of
CSF. Each sample trace represents the average ThT signal of the four wells. Panel a shows the average fluorescence enhancement kinetics for the AD,
DLB and PD patients over time along with the associated standard deviation at each time point. Data points in Panel b indicate the average fluorescence
obtained for each individual case at 48 h. Bars show the average +/− SD for type of case. The dashed line shows the fluorescence threshold for a positive
result. Data points in Panel c show the hours required for the average fluorescence to exceed the threshold for individual cases. Bars show the average
+/− SD for type of case. The dashed line indicates the end of the reaction at 48-h. Blue x symbol indicates sample 15/044 which was tested twice and both
times had only one well crossing fluorescence threshold out of the four replicates. This sample was considered negative, as it did not meet our criteria for
overall sample positivity (see Materials and Methods)
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different conditions, in addition to differences in
absolute seed concentrations, seed characteristics, or
sample matrix components, might have affected the
relative seeding activities observed in brain and CSF
specimens.
Analytical sensitivity using synthetic αSyn fibrils
Finally, to obtain an indication of the analytical sensitivity of
our αSyn RT-QuIC, we prepared synthetic rαSyn fibrils,
spiked them into non-synucleinopathy CSF and assayed ser-
ial dilutions. As little as 100 ag of the synthetic fibril prepa-
rations gave at least 2/4 positive replicate reactions (Fig. 5),
which was at least as sensitive analytically as the αSyn
PMCA assay [35].
Discussion
The ability to detect αSynD as a causative pathological
biomarker for syncleinopathies has important implica-
tions in diagnostics, the development of therapeutics,
and fundamental studies of αSynD-based pathogenesis.
Recent studies have demonstrated diagnostic utility for
αSyn RT-QuIC and closely related αSyn PMCA assays
using CSF specimens [7, 35]. Here we present an αSyn
RT-QuIC assay with similar diagnostic accuracy but
much reduced assay time, i.e. 1–2, rather than 5–13 days.
Sano and colleagues detected αSyn seeding activity of
DLB brain in 3–4 days [32], but as brain has much
higher concentrations of αSynD seeding activity than
CSF (Fig. 4), it is unclear how well their αSyn RT-QuIC
assay would perform with CSF specimens. In any case,
our reduced assay time markedly enhances the cost ef-
fectiveness and practicality of the αSyn RT-QuIC ana-
lyses of CSF. Most of the CSF specimens that we
analyzed were collected relatively early in the disease
course of the given synucleinopathy. The early detection
of αSynD is particularly helpful, firstly, because the ac-
curacy of diagnoses based on other clinical indices is
poorest in the earlier phases of disease, and, secondly,
because the earlier the diagnosis, the earlier that any ap-
propriately targeted therapies can be initiated before fur-
ther tissue damage is done.
Improvements in the early diagnosis of synucleinopa-
thies should also aid in the selection of suitable patients
and controls for therapeutic trials. Furthermore, the abil-
ity to serially measure relative levels of αSynD in treated
and untreated cohorts may provide an alternate means
of monitoring the effects of treatments, especially those
aimed at reducing the burden of αSynD in the brain.
Here we have used end-point dilution analysis for quan-
titation by αSyn RT-QuIC, an approach that has been
helpful in many studies using prion RT-QuIC [23, 24,
39]. A potential alternative approach to quantitation
from RT-QuIC assays is the comparison of lag phases or
times-to-threshold [13, 36] but further studies will be
required to document its utility in αSyn RT-QuIC ana-
lyses of various specimen types.
Consistent with previous findings for αSyn PMCA
[35], αSyn RT-QuIC is capable of detecting sub-
femtogram amounts of rαSyn fibrils that are orders of
magnitude less than those required for more conven-
tional assays such as Western blotting and ELISA,
with typical detection limits for total levels of αSyn,
in the ng and pg range, respectively. The αSyn RT-
QuIC, however, detects only the forms of αSynD cap-
able of seeding further αSyn misfolding. How our
αSyn RT-QuIC sensitivity for synthetic rαSyn amyloid
seeds relates to its absolute sensitivity for any given
form of αSynD in tissues is difficult to determine ac-
curately because different forms of αSynD may have
different seeding capacities per unit mass. Nonethe-
less, based on the average kinetics of seeding using
PD or DLB CSF in Fig. 3, one might estimate femto-
gram levels of seeding capable αSynD may exist in the
CSF of PD or DLB patient when compared to the
synthetic rαSyn amyloid seeding kinetics in Fig. 5.
Furthermore, the difference in the average kinetics of
seeding using PD or DLB CSF may be indicative of a
“strain” difference, similar to what has been observed
from CSF samples from different types of CJD cases
in prion RT-QuIC reactions [8, 25]. While the differ-
ence in the average kinetics is statistically significant
(Welch’s t-test, p < 0.02) between the two seed types,
at this point we do not know the basis for this differ-
ence, or whether it might be diagnostically useful. It
could be due to differences in average seed concen-
tration or seed characteristics, such as potential struc-
tural differences between PD and DLB seeds, that
contribute to kinetic differences in the αSyn RT-QuIC
Fig. 5 End-point dilutions of synthetic seeds spiked into CSF.
Synthetic rαSyn fibrils were generated by continuous shaking at
1000 rpm at 37 °C for 3 days in a 1.5 mL tube containing 100 μL of
1 mg/ml WT rαSyn. Samples were monitored by ThT fluorescence.
Following fibrilization the samples were spiked into non-synucleinopathy
CSF and diluted in 10-fold serial dilutions. Each sample trace represents
the average ± SEM ThT signal of quadruplicate wells. For clarity, data
points were plotted every fourth point and negative controls, which
were all below the positivity threshold, are not displayed
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responses. Testing of much higher numbers of PD
and DLB samples is required to discern whether the
difference in kinetics is maintained and if it is of
diagnostic or mechanistic importance.
As our assay evolved, we saw evidence that several
factors, such as sample volume, SDS concentration,
temperature, and silica beads, strongly influenced the
performance of the assay. However, at present we can-
not be sure of the relative importance of these factors
individually in allowing the assay to be substantially
faster than previously described αSyn RT-QuIC or
PMCA assays. Further testing will be necessary to bet-
ter understand i) the breadth of synucleinopathies that
are detected and/or discriminated by αSyn RT-QuIC
assays, ii) the diagnostic sensitivities and specificities
in clinical settings, iii) the extent to which levels of
αSyn seeding activity in CSF or other diagnostic speci-
mens correlates with disease prognosis, and iv) the
relevance of αSynD seeding activity as a biomarker in
therapeutic trials.
Conclusions
Compared to previously described aSynD seed amplifica-
tion assays, the use of the raSyn substrate preparation,
RT-QuIC reaction conditions, and end-point dilution as-
says that we describe here allowed for much more rapid
detection and quantitation of aSyn seeding activity in
CSF of patients with PD and DLB without reductions in
diagnostic sensitivity or specificity.
Additional files
Additional file 1: Example of K23Q purification chromatograph, and total
protein staining of collected fractions and of the commercial wild-type αSyn
(WT*), and our preparation of the WT and K23Q rαSyn substrates. Absorbance
spectra (blue) and buffer B gradients (green) for purification of K23Q using a
Ni-NTA column (A and B) followed by a Q-HP column (C and D). Arrow in A
denotes a peak representing contaminants. Dashed boxes in A and C denote
the zoomed regions depicted in B and D. The * in C and D denote
contaminants. The red vertical lines in B delineate the peak collected
from the Ni-NTA column between 30 and 75% of buffer B1 (containing
100 and 350 mM imidazole, respectively) for further purification on
the Q-HP column. The red lines in D indicate the peak collected
from the Q-HP column between 30 and 35% of buffer B2 (containing
300 and 350 mM NaCl, respectively) to be used for dialysis and
lyophilization. Panels E and F are a total protein Coomassie Blue
staining of fractions collected from the Ni-NTA and Q-HP column,
respectively. Panel G shows a comparative total protein Coomassie
Blue staining of 2 μg of the commercial wild-type αSyn (WT*), and
both of our WT and K23Q rαSyn substrate preparations. The staining intensity
and apparent molecular weight of the WT* differs from our prepared WT and
K23Q due to the lack of a poly-histidine tag [37], therefore a 5-fold higher
amount of WT* was run in panel H to investigate for potential contaminants
with a higher intensity staining. (TIFF 5283 kb)
Additional file 2: Detection of αSyn seeding activity in BH and CSF
using K23Q (blue), WT (red) and WT* (green; commercial wild-type rαSyn
lacking a 6× histidine tag [7]) substrates as described in Fig. 1 but with
standard deviation. For clarity error bars are only displayed in one direc-
tion. (TIFF 1254 kb)
Additional file 3: Demographic and clinical information for subjects of
this study. (XLSX 17 kb)
Additional file 4: αSyn RT-QuIC end-point dilution analysis of one Par-
kinson’s (PD; 081017) and three dementia with Lewy bodies (DLB;
2004–16, 2006–005 and 2006–020) brain samples listed in Fig. 4. Reac-
tions were seeded in quadruplicate with two μl of either a 10− 4, 10–5,
10− 6 or a 10− 7 brain homogenate (BH) dilutions. Each sample trace
represents the average ThT signal of quadruplicate wells. (TIFF 852 kb)
Additional file 5: End-point dilutions by αSyn RT-QuIC of synucleinopathy
CSF samples listed in Fig. 4. Each sample trace represents the average ThT
signal of quadruplicate wells. Traces represent 15 (Blue), 7.5 (Red), 3.75
(Green), 1.89 (Purple), 0.94 (Orange), 0.47 (Black), 0.2 (Brown) and 0.1 (Dark
Blue) μL of DLBD CSF diluted into normal pooled CSF, when needed, to
give overall CSF sample volumes of 15 µL. (TIFF 1383 kb)
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